Canaccord analyst Mark Massaro lowered his price target for Illumina to $350 from $360 after the company beat on the top and bottom line in Q1 and raised his bottom like 2019 guidance. Massaro tells investors in a research note that he views Q1 as mixed, but reiterates a Buy rating since less than 0.02% of humans have ever been sequenced and clinical sequencing is growing rapidly off an extremely low base.
https://thefly.com/landingPageNews.php?id=2898369
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.